Insertion of Schedule 13 (transitional provisions in relation to EU Exit)U.K.
26. After Schedule 12 insert—
Regulation 56
“SCHEDULE 13U.K.Transitional provisions relating to EU Exit
List of countries for the purpose of the definition of “marketing authorization” on [F1IP completion day] (regulation 2A)
1.—(1) For the purpose of regulation 2A, during the transitional period, the licensing authority must include each EEA State in the list referred to in paragraph (1) of that regulation.
(2) Notwithstanding regulation 2A(3), the licensing authority must not, before the end of the transitional period, remove an EEA State from the list referred to in regulation 2A(1).
(3) In this paragraph, “transitional period” is the period of two years beginning with [F1IP completion day].
List of countries where a sponsor of a clinical trial, or their legal representative, may be established on [F1IP completion day] (regulation 3(11A))
2.—(1) For the purpose of regulation 3, the licensing authority must include each EEA State in the list referred to in paragraph (11A) of that regulation.
(2) Notwithstanding regulation 3(11C), the licensing authority must not, before the end of the transitional period, remove an EEA State from the list referred to in regulation 3(11A).
(3) In this paragraph, “transitional period” is the period of two years beginning with [F1IP completion day].
Import of investigational medicinal products [F2into Great Britain] from EEA States during the transitional period
3.—(1) The condition in regulation 13(2)(b) and the restriction in regulation 36(1) do not apply to an investigational medicinal product that is imported [F3into Great Britain] from an EEA State before the end of the transitional period, provided that the production batch of investigational medicinal products of which the product is a part has been checked and certified by a qualified person pursuant to Article 13(3) and (4) of the Directive.
(2) In this paragraph, “transitional period” is the period of one year beginning with [F1IP completion day].
Approved country for import list on [F1IP completion day] (regulation 43A)
4.—(1) For the purpose of regulation 43A, during the transitional period, the licensing authority must include each EEA State in the list referred to in paragraph (1) of that regulation.
(2) Notwithstanding regulation 43A(3), the licensing authority must not, before the end of the transitional period, remove an EEA State from the list referred to in regulation 43A(1).
(3) In this paragraph, “transitional period” is the period of two years beginning with [F1IP completion day].”.
Textual Amendments
F1Words in reg. 26 substituted (31.12.2020 immediately before IP completion day) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 1 para. 10(a)
F2Words in reg. 26 inserted (31.12.2020 immediately before IP completion day) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 1 para. 10(b)(i)
F3Words in reg. 26 inserted (31.12.2020 immediately before IP completion day) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 1 para. 10(b)(ii)
Commencement Information
I1Reg. 26 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1